Modality
ADC
MOA
CDK4/6i
Target
JAK2
Pathway
Tau
Urothelial CaFTDParkinson's
Development Pipeline
Preclinical
~Oct 2018
→ ~Jan 2020
Phase 1
~Apr 2020
→ ~Jul 2021
Phase 2
~Oct 2021
→ ~Jan 2023
Phase 3
~Apr 2023
→ ~Jul 2024
NDA/BLA
Oct 2024
→ Oct 2030
NDA/BLACurrent
NCT04792601
1,477 pts·FTD
2024-10→2030-10·Completed
1,477 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-10-114.5y awayPh3 Readout· FTD
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2030-10-11 · 4.5y away
FTD
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04792601 | NDA/BLA | FTD | Completed | 1477 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| NBI-3153 | Neurocrine | Approved | Aβ |